Program
Human Growth Hormone
Also written as “somatropin”, “Somatropin” and “PEG-somatropin”.
Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Dwarfism · Growth Disorders · Genetic Diseases, Inborn, led by 15 companies.
Drug pageHuman Growth Hormone: every studyMany companies study it; this page follows only the 117 they lead. All 217 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 340 open or running | phase 4since Sep 13, 2005 | Feb 1, 2005 | none ahead |
| Changchun GeneScience Pharmaceuticalits history only | 194 open or running | phase 4since Nov 27, 2014 | Apr 21, 2011 | Apr 28, 2027phase 4 · NCT07691125 |
| Merck KGaA, Darmstadt, Germanyits history only | 190 open or running | phase 4since Nov 18, 2005 | May 13, 2004 | none ahead |
| Pfizerits history only | 180 open or running | phase 4since Feb 5, 2007 | Sep 9, 2005 | none ahead |
| Eli Lillyits history only | 100 open or running | phase 4since Dec 15, 2005 | Sep 12, 2005 | none ahead |
| LG Chemits history only | 40 open or running | phase 4since Nov 10, 2016 | Dec 29, 2005 | none ahead |
| Daewoong Pharmaceuticalits history only | 20 open or running | phase 3since Jan 19, 2016 | Sep 23, 2011 | none ahead |
| Ferring Pharmaceuticalsits history only | 20 open or running | phase 3since Nov 7, 2005 | Nov 7, 2005 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 4since Dec 4, 2014 | Mar 11, 2004 | none ahead |
| Ipsenits history only | 20 open or running | phase 4since Aug 24, 2011 | Oct 5, 2005 | none ahead |
| Altus Pharmaceuticalsits history only | 10 open or running | phase 2since Feb 2, 2009 | Feb 2, 2009 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Nov 28, 2011 | Nov 28, 2011 | none ahead |
| Clinique Ovoits history only | 10 open or running | phase 4since Oct 24, 2012 | Oct 24, 2012 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Mar 23, 2007 | Mar 23, 2007 | none ahead |
| Zhongshan Sansure Hygene Biomedicineits history only | 11 open or running | phase 3since Sep 2, 2026 | Sep 2, 2026 | Oct 2028phase 3 · NCT07815626 |
Also a collaborator on its studies: Merck Serono S.A.S, France, Merck Serono Co., Ltd., China, Merck Serono S.P.A., Italy, Merck Serono S.A., Geneva, Merck, S.L., Spain and BioPartners.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novo Nordisk only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Feb 1, 2005.
- Dec 16, 2009Phase 1 study in Growth Hormone DisorderNCT01034202 · 56 enrolled · Denmark
- Jul 20, 2011Phase 1 study in Genetic Diseases, InbornNCT01401244 · 30 enrolled · United States
- Dec 29, 2011Phase 1 study in Renal Insufficiency, ChronicNCT01502137 · 21 enrolled · Germany
- Dec 29, 2011Phase 3 study in Growth Hormone DisorderNCT01502124 · 78 enrolled · United States
- Jan 2, 20123 phase 3 studies in Genetic Diseases, InbornNCT01529944, NCT01529840, NCT01518036
- Jan 9, 2012Phase 1 study in Growth DisordersNCT01512095
- Jan 20, 2012Phase 4 study in Genetic Diseases, InbornNCT01518062 · 65 enrolled · Netherlands
- Mar 22, 2012Phase 4 study in Dwarfism, PituitaryNCT01562834 · 22 enrolled · France
- Mar 23, 2012Phase 3 study in Genetic Diseases, InbornNCT01563926 · 168 enrolled · Israel
- Sep 28, 2012Phase 4 study in Foetal Growth ProblemNCT01697644 · 75 enrolled · Netherlands
- Oct 1, 2012Phase 4 study in Dwarfism, PituitaryNCT01698944 · 7 enrolled · Greece
- Nov 22, 20122 phase 4 studiesNCT01734486, NCT01734447
- Jan 24, 2013Phase 3 study in Growth DisordersNCT01778023 · 54 enrolled · Korea, Republic of
- Aug 20, 2013Phase 3 study in Genetic Diseases, InbornNCT01927861 · 51 enrolled · Japan
- Jul 28, 2021Named human growth hormoneINNProposed as its International Nonproprietary Name in WHO's List 125
TargetBeta
“Growth hormone receptor agonist”ChEMBL 37, by rule
Other programs on GHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lonapegsomatropinrule | ascendis-pharma-endocrinology-division-a-s | phase 3 | 6 |
Studies
All 34 Novo Nordisk leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01927861Genetic Diseases, Inborn · Japan | 3 | Completed | Jul 12, 2018 | 51 |
| NCT01778023Growth Disorders · Korea, Republic of | 3 | Completed | Dec 17, 2014 | 54 |
| NCT01734486Genetic Diseases, Inborn · France | 4 | Completed | May 21, 2003 | 31 |
| NCT01734447Foetal Growth Problem · France | 4 | Completed | Apr 30, 2003 | 57 |
| NCT01698944Dwarfism, Pituitary · Greece | 4 | Terminated | Nov 18, 2002 | 7 |
| NCT01697644Foetal Growth Problem · Netherlands | 4 | Completed | May 2005 | 75 |
| NCT01563926Genetic Diseases, Inborn · Israel | 3 | Completed | Oct 10, 2002 | 168 |
| NCT01562834Dwarfism, Pituitary · France | 4 | Completed | Dec 1, 2002 | 22 |
| NCT01518062Genetic Diseases, Inborn · Netherlands | 4 | Completed | Sep 2003 | 65 |
| NCT01518036Genetic Diseases, Inborn · United Kingdom | 3 | Completed | Apr 11, 2004 | 57 |
| NCT01512095Growth Disorders | 1 | Withdrawn | Nov 2013 | 0 |
| NCT01529944Genetic Diseases, Inborn · Sweden | 3 | Completed | Oct 2008 | 22 |
| NCT01529840Genetic Diseases, Inborn · Sweden | 3 | Completed | Sep 2005 | 24 |
| NCT01502137Renal Insufficiency, Chronic · Germany | 1 | Completed | Nov 2005 | 21 |
| NCT01502124Growth Hormone Disorder · United States | 3 | Completed | Mar 5, 2003 | 78 |
| NCT01401244Genetic Diseases, Inborn · United States | 1 | Completed | Sep 27, 2011 | 30 |
| NCT01034202Growth Hormone Disorder · Denmark | 1 | Completed | Jan 2008 | 56 |
| NCT00931476Dwarfism, Pituitary · United States | 1 | Completed | Jun 8, 2000 | 86 |
| NCT00567385Growth Hormone Disorder · Turkey | 4 | Completed | Mar 22, 2004 | 176 |
| NCT00557336Foetal Growth Problem · Spain | 3 | Completed | Jun 29, 2005 | 160 |
| NCT00519844Foetal Growth Problem · France | 4 | Completed | Jan 2006 | 5 |
| NCT00519558Dwarfism, Pituitary · Japan | 3 | Completed | Jan 24, 2005 | 121 |
| NCT00503698Renal Insufficiency, Chronic · United States, Argentina, Brazil and more | 3 | Terminated | Dec 2008 | 712 |
| NCT00262249Growth Disorders · United States | 3 | Completed | May 2004 | 173 |
| NCT00254514Fractures, Bone · Finland, France, Germany and more | 2 | Completed | Oct 2003 | 407 |
| NCT00184769Renal Insufficiency, Chronic · Portugal, Spain | 4 | Completed | Dec 21, 2005 | 16 |
| NCT00184756Foetal Growth Problem · Czech Republic, Finland, Germany and more | 3 | Completed | Jul 2006 | 151 |
| NCT00184743Dwarfism, Pituitary · Japan | 3 | Completed | Dec 28, 2005 | 112 |
| NCT00184730Dwarfism, Pituitary · Japan | 3 | Completed | Sep 2006 | 86 |
| NCT00184717Foetal Growth Problem · Japan | 3 | Completed | Mar 29, 2006 | 98 |
| NCT00184691Foetal Growth Problem · Spain | 3 | Completed | Jun 2005 | 78 |
| NCT00184678Dwarfism, Pituitary · Australia, Austria, Belgium and more | 3 | Completed | Jul 2006 | 161 |
| NCT00184652Renal Insufficiency, Chronic · Denmark, Germany, Hong Kong and more | 2 | Completed | Sep 2005 | 140 |
| NCT00102817Dwarfism, Pituitary · United States | 3 | Completed | Dec 2006 | 149 |
How it is read
Names in the registry
- “somatropin”, 52 entries
- “Somatropin”, 27 entries
- “PEG-somatropin”, 13 entries
- “Saizen®”, 6 entries
- “Genotropin”, 5 entries
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 38 studies
- Turner Syndrome, 10 studies
- Dwarfism, 6 studies
- Growth Disorders, 4 studies
- Genetic Diseases, Inborn, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.